Company Website

Contact information

Octavia Jones
ojones@argenx.com
602-300-7616

George Stangl
gstangl@argenx.com
651-246-8105

Brad Louis
blouis@argenx.com
904-553-9564

Virtual Exhibit Hall Home

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU and the UK. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.
 

Additional Information: 

Core Leave Behind IV

Core Leave Behind Hytrulo

Video Library Page